Cited by 193Influenza Virus Research StudiesVirology and Viral DiseasesRNA Interference and Gene Delivery

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Self-replicating Semliki Forest virus RNA as recombinant vaccine

Zhou, X, Berglund, P, Rhodes, G, Parker, S.E, Jondal, M, Liljeström, P·1994·Vaccine

Open this paper in CoChat — free account

Abstract

Recombinant RNA based on the Semliki Forest virus (SFV) replicon was used to express the nucleoprotein of influenza virus in mice. Two strategies were employed to deliver the RNA. In the first, recombinant RNA was packaged into infectious suicide SFV particles which were used directly for immunization. The second approach involved injection of in vitro-synthesized RNA directly into the quadriceps muscle. Both approaches resulted in the generation of humoral responses with high antibody titres. Immunization with suicide particles showed that a strong, class I-restricted cytotoxic T-cell response can be obtained using only 100 infectious units. We conclude that the self-replicative recombinant SFV RNA may be quite useful as a nucleic acid vaccine.

Integrity signals

Registry

Crossref · 10.1016/0264-410x(94)90074-4

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Current protocols in molecular biology
Sargent, T. (1988) · Analytical Biochemistry · doi:10.1016/0003-2697(88)90147-9 · Cited by 7,281
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,659
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Self-citation
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides
Townsend, A. (1986) · Cell · doi:10.1016/0092-8674(86)90019-x · Cited by 1,711
Genetic immunization is a simple method for eliciting an immune response
Tang, D.-C. C., DeVit, M. J., & Johnston, S. A. (1992) · Nature · doi:10.1038/356152a0 · Cited by 1,504
MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
Germain, R. N. (1994) · Cell · doi:10.1016/0092-8674(94)90336-0 · Cited by 1,431
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations.
Fynan, E. F., Webster, R. G., FULLER, D. H., Haynes, J. R., Santoro, J. C., & Robinson, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11478 · Cited by 1,116
The Biochemistry and Cell Biology of Antigen Processing and Presentation
Germain, R. N., & Margulies, D. H. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.002155 · Cited by 1,003
A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon
Liljeström, P., & Garoff, H. (1991) · Nature Biotechnology · doi:10.1038/nbt1291-1356 · Cited by 905
Self-citation
Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells
Rötzschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J. W., Jung, G., & Rammensee, H. (1990) · Nature · doi:10.1038/348252a0 · Cited by 771

Show all 32 references

Sorted by citations

Items 101–193 of 193

Have mRNA vaccines sentenced DNA vaccines to death?
Cagigi, A., & Douradinha, B. G. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2282065 · Cited by 30
An RNA Vaccine Based on Recombinant Semliki Forest Virus Particles Expressing the Cu,Zn Superoxide Dismutase Protein of Brucella abortus Induces Protective Immunity in BALB/c Mice
Oñate, A. A., Donoso, G., Moraga‐Cid, G., Folch, H., Céspedes, S., & Andrews, E. M. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3294-3300.2005 · Cited by 28
Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA
Adair, R., Patel, A. H., Corless, L., Griffin, S. D. C., Rowlands, D. J., & McCormick, C. J. (2009) · Journal of General Virology · doi:10.1099/vir.2008.006049-0 · Cited by 27
Alphaviral cytotoxicity and its implication in vector development
Rhême, C., Ehrengruber, M. U., & Grandgirard, D. (2004) · Experimental Physiology · doi:10.1113/expphysiol.2004.028142 · Cited by 26
Emerging Therapeutic Modalities against COVID-19
Malik, S., Gupta, A., Zhong, X., Rasmussen, T. P., Manautou, J. E., & Bahal, R. (2020) · Pharmaceuticals · doi:10.3390/ph13080188 · Cited by 27
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection
Krähling, V., Erbar, S., Kupke, A., Nogueira, S. S., Walzer, K. C., Berger, H., Dietzel, E., Halwe, S., Rohde, C., Sauerhering, L., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.10.011 · Cited by 24
Protection of pigs from lethal challenge by a DNA vaccine based on an alphavirus replicon expressing the E2 glycoprotein of classical swine fever virus
Li, N., Jian-jun, Z., He-ping, Z., Sun, Y., Qing-hu, Z., Tong, G., & Qiu, H. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2007.03.018 · Cited by 24
From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Infectious particles derived from Semliki Forest virus vectors encoding murine leukemia virus envelopes
Lebedeva, I. V., Fujita, K., Nihrane, A., & Silver, J. E. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.7061-7067.1997 · Cited by 21
mRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 21
Infectious RNA vaccine protects mice against chikungunya virus infection
Szurgot, I., Ljungberg, K., Kümmerer, B. M., & Liljeström, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-78009-7 · Cited by 19
Self-citation
Efficient gene delivery into mammalian cells by recombinant baculovirus containing a hybrid cytomegalovirus promoter/Semliki Forest virus replicon
Pan, Y., Zhao, Q., Fang, L., Luo, R., Chen, H., & Xiao, S. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1390 · Cited by 18
Vaccines in the 21st Century
Plotkin, S. A. (2001) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70280-4 · Cited by 18
Immune responses in mice vaccinated with a suicidal DNA vaccine expressing the hemagglutinin glycoprotein from the peste des petits ruminants virus
Wang, Y., Liu, G., Shi, L., Li, W., Li, C., Chen, Z., Hongyan, J., Xu, B., & Li, G. (2013) · Journal of Virological Methods · doi:10.1016/j.jviromet.2013.07.031 · Cited by 18
Viral Vectors for Veterinary Vaccines
Sheppard, M. (1999) · Advances in veterinary medicine · doi:10.1016/s0065-3519(99)80014-7 · Cited by 17
Immunogenicity of Semliki Forest virus based self-amplifying RNA expressing Indian HIV-1C genes in mice
Ajbani, S. P., Velhal, S., Kadam, R. B., Patel, V. V., & Bandivdekar, A. H. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.09.010 · Cited by 17
Orthogonal RNA replication enables directed evolution and Darwinian adaptation in mammalian cells
Ma, L., & Lin, Y. (2025) · Nature Chemical Biology · doi:10.1038/s41589-024-01783-2 · Cited by 16
Dendritic cells during infection with HIV-1 and SIV
Ignatius, R., Steinman, R. M., Granelli‐Piperno, A., Messmer, D., Stahl‐Hennig, C., Tenner‐Racz, K., Rácz, P., Frank, I., Zhong, L., Frankel, S. S., et al. (2001) · Elsevier eBooks · doi:10.1016/b978-012455851-9/50074-2 · Cited by 15
Messenger RNA (mRNA) based therapeutics in transforming cardiovascular care: Progress, regulatory challenges and future perspectives
Khan, M., Musazzi, U. M., Manellari, S., Mouawad, N., Damiano, G., Rinaldi, R., Raucci, A., Costantino, S., Paneni, F., Minghetti, P., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107847 · Cited by 16
Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
Hu, C., Liu, J., Cheng, F., Bai, Y., Mao, Q., Xu, M., & Liang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1261243 · Cited by 14
Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs
Duthie, M. S., Machado, B. A. S., Badaró, R. J. D. S., Kaye, P. M., & Reed, S. G. (2022) · Pathogens · doi:10.3390/pathogens11111259 · Cited by 16
1mΨ influences the performance of various positive-stranded RNA virus-based replicons
Miyazato, P., Noguchi, T., Ogawa, F., Sugimoto, T., Fauzyah, Y., Sasaki, R., & Ebina, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-68617-y · Cited by 13
Advanced nanoscale delivery systems for mRNA-based vaccines
Mobasher, M., Ansari, R. A., Castejon, A. M., Barar, J., & Omidi, Y. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130558 · Cited by 13
Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer
Rammensee, H. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2006.01442.x · Cited by 13
Induction of specific human primary immune responses to a Semliki Forest virus?based tumor vaccine in a Trimera mouse model
Ni, B., Gao, W., Zhu, B., Lin, Z., Jia, Z., Zhou, W., Zhao, J., Wang, L., & Wu, Y. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0591-z · Cited by 13
Manipulation of the Semliki Forest virus genome and its potential for vaccine construction
Atkins, G. J., Sheahan, B. J., & Liljeström, P. (1996) · Molecular Biotechnology · doi:10.1007/bf02762410 · Cited by 13
Self-citation
Antigenic Properties of Recombinant Envelope Glycoproteins Derived from T-Cell-Line-Adapted Isolates or Primary Human Immunodeficiency Virus Isolates and Their Relationship to Immunogenicity
Brand, D., Lemiale, F., Thibault, G., Verrier, B., Lebigot, S., Roingeard, P., Buzelay, L., Brunet, S., & Barin, F. (2000) · Virology · doi:10.1006/viro.2000.0322 · Cited by 13
Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects
Wei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., & Zhai, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524317 · Cited by 16
Immunogenicity of a DNA-launched replicon-based canine parvovirus DNA vaccine expressing VP2 antigen in dogs
Dahiya, S. S., Saini, M., Kumar, P., & Gupta, P. K. (2012) · Research in Veterinary Science · doi:10.1016/j.rvsc.2012.01.017 · Cited by 12
Muscle Regeneration and RNA: New Perspectives for Ancient Molecules
Buonaiuto, G., Desideri, F., Taliani, V., & Ballarino, M. (2021) · Cells · doi:10.3390/cells10102512 · Cited by 11
Alphavirus-Based Vaccines
Lundstrom, K. H. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6869-5_13 · Cited by 12
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Sa-nguanmoo, N., Namdee, K., Khongkow, M., Ruktanonchai, U., Zhao, Y., & Liang, X. (2021) · Nano Research · doi:10.1007/s12274-021-3832-y · Cited by 12
What's going on in vaccine technology?
Russo, S., Turin, L., Zanella, A., Ponti, W., & Poli, G. (1997) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199705)17:3 · Cited by 12
Alphavirus Vectors in Vaccine Development
Lundstrom, K. H. (2012) · Journal of Vaccines & Vaccination · doi:10.4172/2157-7560.1000139 · Cited by 11
Alphaviral Encephalitides
Weaver, S. C., & Paessler, S. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369408-9.00021-4 · Cited by 11
RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
Abdelzaher, H. M., Gabr, A. S., Saleh, B. M., Gawad, R. M. A., Nour, A. A., & Abdelnaser, A. (2021) · Vaccines · doi:10.3390/vaccines9111211 · Cited by 12
The Bright Future of mRNA as a Therapeutic Molecule
Vélez, D. E., Torres, B. L., & Hernández, G. (2025) · Genes · doi:10.3390/genes16040376 · Cited by 11
Immunogenicity of Recombinant Envelope Glycoproteins Derived From T-Cell Line-Adapted Isolates or Primary HIV Isolates
Lemiale, F., Brand, D., Lebigot, S., Verrier, B., Buzelay, L., Brunet, S., & Barin, F. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200104150-00003 · Cited by 10
Regulatory Issues in the Use of DNA Vaccines
Minor, P. D. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44742.x · Cited by 9
Design principles and applications of synthetic self‐replicating RNAs
Wagner, A., & Mutschler, H. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1803 · Cited by 8
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
Kŕause, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020308 · Cited by 8
Progress in vaccine development for infectious diseases—a Keystone Symposia report
Cable, J., Graham, B. S., Koup, R. A., Seder, R. A., Karikó, K., Pardi, N., Barouch, D. H., Sharma, B., Rauch, S., Nachbagauer, R., et al. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14975 · Cited by 8
A single dose of a suicidal DNA vaccine induces a specific immune response in salmonids
Castells, M., TORRE, J. L. L., Grigera, P. R., & Poggio, T. V. (2014) · Journal of Fish Diseases · doi:10.1111/jfd.12274 · Cited by 7
RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens
Kola, N. S., Patel, D., & Thakur, A. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3890-3_21 · Cited by 6
Recent advances in development and delivery of non-viral nucleic acid therapeutics for brain tumor therapy
Kögel, D., Temme, A., & Aigner, A. M. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108762 · Cited by 7
Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine
Couty, J., Crain‐Denoyelle, A., Gerbaud, S., Labasque, M., Marchiol, C., FRADELIZI, D., Boudaly, S., Guettier, C., Vignuzzi, M., van der Werf, S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0448-3 · Cited by 6
Are trans‐complementation systems suitable for hepatitis C virus life cycle studies?
Fournier, C., Duverlie, G., & Castelain, S. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12069 · Cited by 6
Alphavirus-Based Expression Systems
Rice, C. M. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-1382-1_5 · Cited by 6
Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review)
Babaeimarzangou, S. S., Zaker, H., Soleimannezhadbari, E., Shamsi-Gamchi, N., Kazeminia, M., Tarighi, S., Seyedian, H., Tsatsakis, A. M., Spandidos, D. A., & Margina, D. M. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11741 · Cited by 5
Malaria & mRNA Vaccines: A Possible Salvation from One of the Most Relevant Infectious Diseases of the Global South
Borkens, Y. (2023) · Acta Parasitologica · doi:10.1007/s11686-023-00712-y · Cited by 5
Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis
Chen, Z., Liu, Z., Feng, Y., Shi, A., Wu, L., Sang, Y., & Li, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1259788 · Cited by 7
Utility of the Sindbis replicon system as an Env-targeted HIV vaccine
Miller, A., Wheatley, A. K., Campbell, S. M., Siebentritt, C., & Purcell, D. F. J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.064 · Cited by 5
Self Replicating Gene Vaccine Carrying P1-2A Gene of FMDV Serotype O and its Effects on the Immune Responses of Cattle
Nagarajan, G., Ravikumar, P., Kumar, C. A., Reddy, G. R., Dechamma, H. J., & Suryanarayana, V. V. S. (2011) · Indian Journal of Virology · doi:10.1007/s13337-011-0032-5 · Cited by 5
Immunogenicity of Recombinant Envelope Glycoproteins Derived From T-Cell Line-Adapted Isolates or Primary HIV Isolates
Lemiale, F., Brand, D., Lebigot, S., Verrier, B., Buzelay, L., Brunet, S., & Barin, F. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200104150-00003 · Cited by 5
Production and delivery of recombinant subunit vaccines
Andersson, C. (2000) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 5
Unraveling the potential: mRNA therapeutics in oncology
Gawalski, K., Przybyszewska, W., Hunia, J., Gawalska, A., & Rymarz, A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1643444 · Cited by 6
Vacunas en el siglo veintiuno
Plotkin, S. A. (2002) · Vacunas · doi:10.1016/s1576-9887(02)70270-7 · Cited by 4
Vaccination with Recombinant Suicidal DNA/RNA
Berglund, P., Fleeton, M. N., Smerdou, C., Tubulekas, I., Sheahan, B. J., Atkins, G. J., & Liljestræm, P. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46860-3_107 · Cited by 4
Self-citation
Generation of CTL responses using Kunjin replicon RNA
Ward, S. M., Tindle, R. W., Khromykh, A. A., & Gowans, E. J. (2003) · Immunology and Cell Biology · doi:10.1046/j.0818-9641.2002.01137.x · Cited by 4
Immune Pathways Used in Nucleic Acid Vaccination
Rhodes, G. H. (1999) · Elsevier eBooks · doi:10.1016/b978-012358465-6/50029-3 · Cited by 4
Self-citation
A Historical Overview on mRNA Vaccine Development
Verbeke, R., Cheng, M. H. Y., & Cullis, P. R. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch1 · Cited by 5
Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA
Zimmermann, L., & Erbar, S. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_5 · Cited by 3
mRNA Vaccination and Personalized Cancer Therapy
Kreiter, S., Diken, M., & Şahin, U. (2014) · Springer eBooks · doi:10.1007/978-3-319-05104-8_9 · Cited by 3
Vaccines in the 21st Century
Plotkin, S. A. (2002) · Hybridoma and Hybridomics · doi:10.1089/153685902317401744 · Cited by 3
The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection
Xue, V. W., Wong, S. C. C., Li, B., & Cho, W. C. S. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2218083 · Cited by 2
Application of self-amplifying mRNA technology in the development of infectious disease vaccines
Li, X., Wang, X., & Zhang, B. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0902 · Cited by 3
Alphavirus Vectors: Highly Efficient Systems for Transient Gene Expression
Smerdou, C., & Liljeström, P. (2000) · Cell engineering · doi:10.1007/978-94-011-4315-8_7 · Cited by 2
Self-citation
Recombinant Self-Replicating RNA Vaccines
Liljeström, P. (1995) · Springer eBooks · doi:10.1007/978-1-4613-0357-2_18 · Cited by 2
Self-citation
Tecnologías de producción de vacunas (III). Vacunas génicas
Salleras, L. (2002) · Vacunas · doi:10.1016/s1576-9887(02)70303-8 · Cited by 2
Sindbis Virus Replicon-Based SARS-CoV-2 and Dengue Combined Vaccine Candidates Elicit Immune Responses and Provide Protective Immunity in Mice
Zhu, Y., He, W., Hu, R., Liu, X., Li, M., & Liu, Y. (2024) · Vaccines · doi:10.3390/vaccines12111292 · Cited by 1
Immune-Activating Mechanisms of Replicase-Based DNA and RNA Vaccines and Their Role in Immune-Apoptosis
Leitner, W. W. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0439-2_3 · Cited by 1
Lack of expression of hepatitis C virus core protein in human monocyte-erived dendritic cells using recombinant semliki forest virus
Navas, M. C., Stoll‐Keller, F., & Pavlovic, J. (2019) · Acta Biológica Colombiana · doi:10.15446/abc.v24n3.79368 · Cited by 1
Replicons from positive strand RNA viruses for naked RNA immunization against influenza
Vignuzzi, M., Gerbaud, S., van der Werf, S., & Escriou, N. (2001) · International Congress Series · doi:10.1016/s0531-5131(01)00409-5 · Cited by 1
Development of vaccines and experimental models for chronic infections caused by the hepatitis C virus
Frelin, L. (2004) · Figshare · Cited by 1
Alphavirus replicon-based strategies for vaccination
Knudsen, M. (2014) · Figshare · Cited by 1
Evaluation of new strategies to elicit neutralizing antibodies against HIV-1
Forsell, M. N. E. (2008) · Figshare · Cited by 1
RNA ‐Based Therapies
Pascolo, S. (2010) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse028
PROTEIN EXPRESSION IN MAMMALIAN CELLS USING SINDBIS VIRUS
Bennett, R. P. (1999) · Elsevier eBooks · doi:10.1016/b978-012253840-7/50011-0
Targeted Immune Design Using RNA Immunization
Garrity, R. R. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08055.x
Historical Development Process of mRNA Vaccines and SARS-CoV-2 Pandemic
GÜNEŞ, N., & Karabulut, Ş. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.14
Zur Psychiatrie von Corona
Spitzer, M. (2021) · Nervenheilkunde · doi:10.1055/a-1246-0550
Annotated References by Year
(2001) · Elsevier eBooks · doi:10.1016/b978-012455851-9/50085-7
Malaria-Antigene in der Ära der mRNA-Impfstoffe
Borkens, Y. (2022) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-022-01554-0
Biotechnology applications in infectious disease
Lundstrom, K. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.00010-4
Basic biotechnology applications in viral diseases
Ilahi, N. E., & Bhatti, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.00007-4
Experiments and Clinical Trials Against Infectious Diseases
Lemonnier, J., & Lemonnier, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-39300-6_12
Перемога мРНК-вакцин над пандемією коронавірусу SARS-CoV-2, який викликає захворювання COVID-19, або як синтетична мРНК прослизнула повз вроджений імунний захист клітини
Комісаренко, С. В., & Романюк, С. И. (2023) · Visnik Nacional noi academii nauk Ukrai ni · doi:10.15407/visn2023.12.003
Self-amplifying mRNA expression is governed by mitochondrial machinery and ACSL4Preprint
Tshering, L. F., Wang, C., Xiang, Q., Kundu, S., Solórzano, A., Chaparro‐Riggers, J. F., Lin, L., & Paksa, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659366
Optimising a mRNA Vaccine platform against HIV-1 : from the in vitro transcription design to envelope protein expression
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Advances in RNA-Based Therapeutics in Oncology
Lopes-Cardoso, H., Panão-Costa, J., Amaral, A. T., Soares-Gonçalves, J., Neves, B. F., Voronovska, A., Batista, A., Biscaia-Caleiras, M., Fonseca, N. A., Simões, S., et al. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_19
Nanotechnology-based self-amplifying RNA
Deng, Q., Zhou, H., Zhao, S., Zhu, J., Xie, Z., Li, L., Xu, Y., Huang, Y., Dong, P., Cao, T., et al. (2026) · iPharma · doi:10.1016/j.iphar.2026.100006
In vivo CAR‑T therapy: recent progress and future directions
Wang, W., Cai, Y., Yang, X., & Xu, H. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00050-4
Designing a Vaccine Against HIV
Schultz, A. M. (1999) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-59955-2_14

Authors: Zhou, X., Berglund, P., Rhodes, G., Parker, S. E., Jondal, M., & Liljeström, P.
Affiliations: Karolinska Institutet (SE)
Vical (United States) (US)
Corresponding author: Liljeström, P
ORCID: Zhou, X
Berglund, P
Liljeström, P
Venue: Vaccine
Publisher: Elsevier BV
Published: 1994-12
Volume: 12
Issue: 16
Pages: 1510-1514
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/0264-410x(94)90074-4
OpenAlex: W2006168695
Cited by: 193
References: 32
Citations by year: 2026: 3 · 2025: 6 · 2024: 9 · 2023: 17 · 2022: 10 · 2021: 13 · 2020: 8 · 2019: 6 · 2018: 1 · 2017: 3 · 2015: 3 · 2014: 7 · 2013: 5 · 2012: 4
FWCI: 6.37
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Vaccine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: Semliki Forest virus, nucleic acid vaccines, influenza nucleoprotein, humoral immune response, cytotoxic T lymphocytes, self-replicating RNA
MeSH terms: Animals, Mice, Inbred BALB C, RNA, Viral, Semliki forest virus, T-Lymphocytes, Cytotoxic, Transfection, Vaccines, Synthetic, Viral Vaccines, Virus Replication, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Self-replicating Semliki Forest virus RNA as recombinant vaccine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks